Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer

AbbVie ABBV and Bristol-Myers Squibb Company BMY entered into a deal to evaluate the combination of AbbVie’s investigational antibody drug conjugate, ABBV-399, and Bristol-Myers Squibb’s immune-oncology drug, Opdivo (nivolumab), in c-Met overexpressing non-small cell lung cancer (NSCLC). Currently, the combination is in a phase I study that evaluates the…